FGF2 and myeloid sarcoma: In post-mortem and in brain tissue from patients with progressive MS, FGF2 is expressed stronger than in controls, however, in this study no correlations were found between FGF2 expression and parameters such as age, disease duration, or the total number of MS lesions [91,92].